-+ 0.00%
-+ 0.00%
-+ 0.00%

BOEHRINGER INGELHEIM: START OF PHASE II CLINICAL TRIAL EVALUATING ITS INVESTIGATIONAL TRIPLE GLP-1/GIP/NPY2 RECEPTOR AGONIST, BI 3034701

路透·07/16/2026 05:02:12

登录查看新闻详情